VTRS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Viatris Inc. (VTRS) is not an ideal buy at this moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While the stock has some positive catalysts, the overbought technical indicators, weak financial performance, and hedge fund selling outweigh the potential benefits. A hold position is recommended until clearer growth trends or better entry points emerge.
The stock is currently in an overbought condition with an RSI of 80.011, suggesting a potential pullback. The MACD is positive but contracting, indicating weakening bullish momentum. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the price is nearing resistance at R1: 16.025. The stock has a 30% chance to decline slightly (-0.05%) in the next day and a moderate chance of short-term gains (2.8% in the next week).
UBS and Argus upgraded the stock to Buy recently, citing improving growth, cost savings, and an attractive entry point.
The company's pipeline and margin expansion are viewed positively by analysts.
The stock trades at a low multiple, which could attract value investors.
Hedge funds are aggressively selling, with a 247.32% increase in selling over the last quarter.
Financial performance in Q3 2025 was weak, with a significant drop in net income (-235.23% YoY) and EPS (-237.50% YoY).
The stock is overbought based on RSI, indicating a potential short-term pullback.
In Q3 2025, revenue increased slightly by 0.23% YoY to $3.76B, but net income dropped significantly to -$128.2M (-235.23% YoY). EPS also fell to -0.11 (-237.50% YoY), and gross margin declined to 39.84% (-6.94% YoY). Overall, the financial performance shows weak profitability and growth trends.
Recent analyst ratings are mixed but leaning positive. UBS upgraded the stock to Buy with an $18 price target, citing growth and cost savings. Argus also upgraded to Buy with a $15 price target, highlighting the company's strategy and attractive valuation. However, JPMorgan and Piper Sandler maintain Neutral ratings, suggesting cautious optimism.
